Journal of Hepatology
Volume 51, Issue 3 , Pages 557-564, September 2009

Hepatocyte GP73 expression in Wilson disease

  • Lorinda M. Wright

      Affiliations

    • Division of Gastroenterology, Hepatology and Nutrition, Loyola University Medical Center, 2160 South 1st Ave., Maywood, IL 60153, USA
    • Hines VA Medical Center, Hines, IL, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 708 2025717; fax: +1 7082164113.
  • ,
  • Dominik Huster

      Affiliations

    • Department of Medicine II, University of Leipzig, Leipzig, Germany
  • ,
  • Svetlana Lutsenko

      Affiliations

    • Department of Biochemistry and Molecular Biology, Oregon Health & Science University, Portland, OR, USA
  • ,
  • Fritz Wrba

      Affiliations

    • Department of Clinical Pathology, Medical University of Vienna, Vienna, Austria
  • ,
  • Peter Ferenci

      Affiliations

    • Department of Internal Medicine 4, Medical University of Vienna, Vienna, Austria
  • ,
  • Claus J. Fimmel

      Affiliations

    • Division of Gastroenterology, Hepatology and Nutrition, Loyola University Medical Center, 2160 South 1st Ave., Maywood, IL 60153, USA
    • Hines VA Medical Center, Hines, IL, USA

Received 5 January 2009; received in revised form 29 April 2009; accepted 25 May 2009. published online 25 June 2009.

Associate Editor: Y. Deugnier

Background/Aims

Wilson disease (WD) is a disorder of copper transport caused by mutations within the ATP7B gene. WD is phenotypically variable and can present with predominantly hepatic or neurologic manifestations. The mechanisms responsible for this variability are unknown. GP73, a Golgi membrane protein, is expressed in hepatocytes in response to acute and chronic liver disease.

Methods

Hepatocyte GP73 expression was examined in the livers of WD patients by semiquantitative immunohistochemistry. GP73 mRNA levels were measured in mice with a deletion of the WD gene (Atp7b−/−) by real-time PCR, and these values were compared to the concomitant histological abnormalities and previously reported copper levels.

Results

Hepatocyte GP73 expression was more frequently observed in patients with hepatic versus neurologic presentation (79% vs. 30%, p<0.05). Furthermore, GP73 expression was significantly higher (44.7±14.0 vs. 2.0±0.81, p<0.05) in patients with hepatic phenotype. In Atp7b−/− mice, GP73 mRNA was significantly elevated at 20–46 weeks of age, coincident with extensive hepatic inflammation and fibrosis, but not at 6 weeks, when hepatic histology was normal despite significant copper overload. GP73 mRNA levels normalized concomitantly with the resolution of hepatic injury at 60-weeks. However, in tumor-like nodules GP73 was strikingly elevated.

Conclusion

Increased hepatocyte GP73 expression is more commonly a feature of hepatic than neurologic WD, and is triggered in response to inflammation, fibrosis, and dysplasia, rather than copper overload.

Abbreviations: WD, Wilson disease, ATP7B, ATPase copper transporting, beta polypeptide, GP73, Golgi protein 73kDa, HCC, hepatocellular carcinoma, CNS, central nervous system, KFR, Kayser–Fleischer rings, Cpl, ceruloplasmin, H & E, hematoxylin & eosin, IH, immunohistochemistry, RT-PCR, real-time polymerase chain reaction, GAPDH, glyceraldehyde-3-phosphate dehydrogenase, Dx, diagnosis, ATOX1, metallochaperone antioxidant-1, COMMD1, copper metabolism MURR1 domain, PLZF, promyelocytic leukemia zinc finger protein, MINT, Molecular INTeraction database

Keywords: Atp7b, Copper, Golgi, Knockout mouse, Liver

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study was supported by an NIH grant (R21 DK075659) to S.L. The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

PII: S0168-8278(09)00398-5

doi:10.1016/j.jhep.2009.05.029

Journal of Hepatology
Volume 51, Issue 3 , Pages 557-564, September 2009